Glaxosmithkline Regulatory News (GSK)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Charles Bancroft

b)

Position/status

Senior Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Release of 17,446 notional ADSs from the GSK Non-Executive Director Share Allocation Arrangements following the termination of those arrangements, the withholding of 1,602 notional ADSs for tax and the final release of 15,843 ADSs representing the balance. These ADSs will be held by Charles Bancroft until he retires from the Board. A residual cash payment of $32.60 will be paid to Charles Bancroft.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$38.805

15,843

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-03-25

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Anne Beal

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Release of 1,988 notional ADSs from the GSK Non-Executive Director Share Allocation Arrangements following the termination of those arrangements, the withholding of 1,018 notional ADSs for tax and the final release of 970 ADSs representing the balance. These shares will be held by Dr Anne Beal until she retires from the Board. A residual cash payment of $4.66 will be paid to Dr Anne Beal.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$38.805

970

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-03-25

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Dietz

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Release of 1,760 notional ADSs from the GSK Non-Executive Director Share Allocation Arrangements following the termination of those arrangements, the withholding of 909 notional ADSs for tax and the final release of 850 ADSs representing the balance. These shares will be held by Dr Hal Dietz until he retires from the Board. A residual cash payment of $38.42 will be paid to Dr Hal Dietz.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$38.805

850

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-03-25

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Jesse Goodman

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W2044

b)

Nature of the transaction

Release of 13,924 notional ADSs from the GSK Non-Executive Director Share Allocation Arrangements following the termination of those arrangements, the withholding of 7,082 notional ADSs for tax and the final release of 6,842 ADSs representing the balance. These shares will be held by Dr Jesse Goodman until he retires from the Board. A residual cash payment of $11.64 will be paid to Dr Jesse Goodman.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$38.805

6,842

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-03-25

f)

Place of the transaction

New York Stock Exchange (XNYS)